Scholarlink

Background <p>Neoadjuvant chemotherapy (NAC) leads to a nodal pathologic complete response (pCR) in approximately 70% of breast cancer patients, especially in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative subtypes. However, sentinel lymph node (SLN)-mapping after NAC remains challenging due to lower identification and higher false-negative rates compared with early-stage breast cancer. This study aimed to evaluate the efficacy of a multimodal SLN-mapping approach after NAC.</p> Methods <p>This prospective, single-center, randomized controlled trial enrolled 270 patients with breast cancer receiving NAC between May 2021 and July 2024 and randomized them (1:1:1) to arm A (radioisotope [RI] + indocyanine green fluorescence [ICG-F]), arm B (RI + vital dye [indigo carmine]), and arm C (ICG-F + vital dye). The primary outcome of SLN-identification rate and the secondary outcome of SLN-operation time were analyzed.</p> Result <p>Interim results showed SLN-identification rates of 95% in arm A, 92% in arm B, and 79% in arm C, with a significant difference between arms A and C (0.1597; <i>p =</i> 0.0055). The final analysis comparing only arms A and B showed SLN-identification rates of 92.6% (100/108) and 90.6% (96/106), respectively (<i>p =</i> 0.2967), with a significantly shorter mean time to first SLN detection in arm B than in arm A (7 vs. 8&#xa0;min; <i>p =</i> 0.0046). The intra-arm detection rates differed significantly: arm A (RI, 96.0%; ICG-F, 92.0%; <i>p =</i> 0.232) versus arm B (RI, 97.9%; vital dye, 72.9%; <i>p</i> &lt; 0.0001).</p> Conclusion <p>Multimodal SLN-mapping demonstrated high post-NAC identification rates without significant intra-arm differences in the SLN-identification rates, whereas SLN-detection rates differed by the method for each arm. For patients with breast cancer, RI + ICG-F SLN-mapping is an effective dual-method post-NAC approach.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical Application of Multimodal Sentinel Lymph Node-Mapping Method for Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: A Final Analysis

  • 期刊论文

  • 发表日期：

    2025年6月30日

查看全文
  • Eun-Gyeong Lee,
  • Dong-Eun Lee,
  • So-Youn Jung,
  • Jai Hong Han,
  • Seok-Ki Kim,
  • Heejung Chae,
  • Sung Hoon Sim,
  • Keun Seok Lee,
  • Seeyoun Lee

摘要

Background

Neoadjuvant chemotherapy (NAC) leads to a nodal pathologic complete response (pCR) in approximately 70% of breast cancer patients, especially in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative subtypes. However, sentinel lymph node (SLN)-mapping after NAC remains challenging due to lower identification and higher false-negative rates compared with early-stage breast cancer. This study aimed to evaluate the efficacy of a multimodal SLN-mapping approach after NAC.

Methods

This prospective, single-center, randomized controlled trial enrolled 270 patients with breast cancer receiving NAC between May 2021 and July 2024 and randomized them (1:1:1) to arm A (radioisotope [RI] + indocyanine green fluorescence [ICG-F]), arm B (RI + vital dye [indigo carmine]), and arm C (ICG-F + vital dye). The primary outcome of SLN-identification rate and the secondary outcome of SLN-operation time were analyzed.

Result

Interim results showed SLN-identification rates of 95% in arm A, 92% in arm B, and 79% in arm C, with a significant difference between arms A and C (0.1597; p = 0.0055). The final analysis comparing only arms A and B showed SLN-identification rates of 92.6% (100/108) and 90.6% (96/106), respectively (p = 0.2967), with a significantly shorter mean time to first SLN detection in arm B than in arm A (7 vs. 8 min; p = 0.0046). The intra-arm detection rates differed significantly: arm A (RI, 96.0%; ICG-F, 92.0%; p = 0.232) versus arm B (RI, 97.9%; vital dye, 72.9%; p < 0.0001).

Conclusion

Multimodal SLN-mapping demonstrated high post-NAC identification rates without significant intra-arm differences in the SLN-identification rates, whereas SLN-detection rates differed by the method for each arm. For patients with breast cancer, RI + ICG-F SLN-mapping is an effective dual-method post-NAC approach.